High efficacy treatment since the first attack - an important step in the treatment of multiple sclerosis?
Abstract
Multiple sclerosis (MS) is a serious chronic disease of the central nervous system, in whose pathogenesis both autoimmune inflammation and neurodegeneration play a role from the beginning. Therapeutic options for MS have expanded significantly in recent years.
Early initiation of high efficacy treatment after the first attack is now at the forefront of interest, as reimbursement criteria now allow it for monoclonal antibodies targeting the CD20 molecule in the Czech Republic. Ofatumumab can also be administered at home, subcutaneously once a month.
However, even in light of these favourable prospects, we must not forget the need for a comprehensive individual approach, including non-pharmacological interventions, especially influencing lifestyle factors.